Literature DB >> 35533066

Understanding epilepsy in IDH-mutated gliomas: towards a targeted therapy.

Frank Winkler1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35533066      PMCID: PMC9435490          DOI: 10.1093/neuonc/noac122

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  11 in total

1.  Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

Authors:  Darcy A Krueger; Marguerite M Care; Katherine Holland; Karen Agricola; Cynthia Tudor; Prajakta Mangeshkar; Kimberly A Wilson; Anna Byars; Tarek Sahmoud; David Neal Franz
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

2.  Synaptic input to brain tumors: clinical implications.

Authors:  Varun Venkataramani; Dimitar Ivanov Tanev; Thomas Kuner; Wolfgang Wick; Frank Winkler
Journal:  Neuro Oncol       Date:  2021-01-30       Impact factor: 12.300

Review 3.  Seizures and gliomas--towards a single therapeutic approach.

Authors:  Gilles Huberfeld; Charles J Vecht
Journal:  Nat Rev Neurol       Date:  2016-03-11       Impact factor: 42.937

4.  DNA Methylation subclass Receptor Tyrosine Kinase II (RTK II) is predictive for seizure development in glioblastoma patients.

Authors:  Franz L Ricklefs; Richard Drexler; Kathrin Wollmann; Alicia Eckhardt; Dieter H Heiland; Thomas Sauvigny; Cecile Maire; Katrin Lamszus; Manfred Westphal; Ulrich Schüller; Lasse Dührsen
Journal:  Neuro Oncol       Date:  2022-05-02       Impact factor: 12.300

5.  IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation.

Authors:  Armin Mortazavi; Islam Fayed; Muzna Bachani; Tyrone Dowdy; Jahandar Jahanipour; Anas Khan; Jemima Owotade; Stuart Walbridge; Sara K Inati; Joseph Steiner; Jing Wu; Mark Gilbert; Chun Zhang Yang; Mioara Larion; Dragan Maric; Alexander Ksendzovsky; Kareem A Zaghloul
Journal:  Neuro Oncol       Date:  2022-09-01       Impact factor: 13.029

6.  Brain tumour cells interconnect to a functional and resistant network.

Authors:  Matthias Osswald; Erik Jung; Felix Sahm; Gergely Solecki; Varun Venkataramani; Jonas Blaes; Sophie Weil; Heinz Horstmann; Benedikt Wiestler; Mustafa Syed; Lulu Huang; Miriam Ratliff; Kianush Karimian Jazi; Felix T Kurz; Torsten Schmenger; Dieter Lemke; Miriam Gömmel; Martin Pauli; Yunxiang Liao; Peter Häring; Stefan Pusch; Verena Herl; Christian Steinhäuser; Damir Krunic; Mostafa Jarahian; Hrvoje Miletic; Anna S Berghoff; Oliver Griesbeck; Georgios Kalamakis; Olga Garaschuk; Matthias Preusser; Samuel Weiss; Haikun Liu; Sabine Heiland; Michael Platten; Peter E Huber; Thomas Kuner; Andreas von Deimling; Wolfgang Wick; Frank Winkler
Journal:  Nature       Date:  2015-11-04       Impact factor: 49.962

7.  Glutamatergic synaptic input to glioma cells drives brain tumour progression.

Authors:  Varun Venkataramani; Dimitar Ivanov Tanev; Christopher Strahle; Alexander Studier-Fischer; Laura Fankhauser; Tobias Kessler; Christoph Körber; Markus Kardorff; Miriam Ratliff; Ruifan Xie; Heinz Horstmann; Mirko Messer; Sang Peter Paik; Johannes Knabbe; Felix Sahm; Felix T Kurz; Azer Aylin Acikgöz; Frank Herrmannsdörfer; Amit Agarwal; Dwight E Bergles; Anthony Chalmers; Hrvoje Miletic; Sevin Turcan; Christian Mawrin; Daniel Hänggi; Hai-Kun Liu; Wolfgang Wick; Frank Winkler; Thomas Kuner
Journal:  Nature       Date:  2019-09-18       Impact factor: 49.962

8.  IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy.

Authors:  Andrew Neal; Patrick Kwan; Terence John O'Brien; Michael E Buckland; Michael Gonzales; Andrew Morokoff
Journal:  Epilepsy Behav       Date:  2017-12-22       Impact factor: 3.337

9.  The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma.

Authors:  Anh Huan Vo; Prakash Ambady; David Spencer
Journal:  Epilepsy Behav Rep       Date:  2022-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.